OKYO: OKYO Pharma Inc Company Aggregate Debts

The clinical success of molecules targeting corneal pain and M&A potential define the development trajectory of OKYO Pharma Limited (OKYO). The debt burden dynamics on the GURU.Markets chart visualize the financial load, where the value of 0.00 serves as the baseline indicator. The brand focuses on eliminating the causes of eye discomfort, and the market has already priced in the anticipation of Phase II trial results in the absence of revenue.

The absence of commercial products and high costs associated with ophthalmological research leave OKYO Pharma Limited (OKYO) vulnerable to the risk of capital depletion. Debt dynamics reflect the balance between securing liquidity for drug development and the risk of bankruptcy; therefore, the amount of borrowed capital serves as an indicator of the issuer's financial stability amid high uncertainty regarding clinical trial results.